Barclays PLC Has $255,000 Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Barclays PLC boosted its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 122.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 129,839 shares of the company’s stock after buying an additional 71,463 shares during the quarter. Barclays PLC owned approximately 0.14% of Caribou Biosciences worth $255,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its stake in shares of Caribou Biosciences by 16.8% in the second quarter. The Manufacturers Life Insurance Company now owns 36,489 shares of the company’s stock worth $60,000 after acquiring an additional 5,244 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Caribou Biosciences by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after purchasing an additional 6,768 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Caribou Biosciences during the third quarter worth $28,000. American Century Companies Inc. raised its stake in Caribou Biosciences by 15.2% during the second quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock worth $205,000 after buying an additional 16,530 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in Caribou Biosciences in the second quarter valued at $30,000. Institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Citigroup decreased their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Bank of America decreased their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock opened at $1.53 on Tuesday. The stock has a market capitalization of $138.54 million, a PE ratio of -0.93 and a beta of 2.34. Caribou Biosciences, Inc. has a 52 week low of $1.50 and a 52 week high of $8.33. The stock has a 50 day moving average price of $1.88 and a two-hundred day moving average price of $2.00.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Research analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.